Last update 08 May 2025

Atilotrelvir/Ritonavir

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
GST-HG171/Ritonavir, 泰阿特韦/利托那韦, Tazovid
+ [1]
Target
HIV-1 protease x SARS-CoV-2 3CLpro
Action
inhibitors
Mechanism
HIV-1 protease inhibitors(Human immunodeficiency virus type 1 protease inhibitors), SARS-CoV-2 3CLpro inhibitors(SARS-CoV-2-3C-like-proteinase inhibitors)
Therapeutic Areas
Infectious DiseasesRespiratory Diseases
Active Indication
COVID-19
Inactive Indication-
Originator Organization
Fujian Akeylink Biotechnology Co., Ltd
Active Organization
Fujian Akeylink Biotechnology Co., Ltd
Inactive Organization-
License Organization-
Drug Highest PhaseApproved
First Approval Date
China (23 Nov 2023),
COVID-19
RegulationConditional marketing approval (China), Special Review Project (China)
Login to view timeline

Structure/Sequence

Molecular FormulaC24H32F3N5O4
InChIKeyGTRJFXDJASEGSW-KBCNZALWSA-N
CAS Registry2850365-55-6
View All Structures (2)

Related

4
Clinical Trials associated with Atilotrelvir/Ritonavir
NCT06087055
/ CompletedPhase 1
An Open Labe Study to Evaluate the Drug-Drug Interaction of Itraconazole With GST-HG171/Ritonavir in Healthy Adult Chinese Participants
NCT06084507
/ Active, not recruitingPhase 1
Food Effects Study of GST-HG171 Tablets Combined With Ritonavir in Healthy Chinese Participants
NCT05656443
/ CompletedPhase 2/3
A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase Ⅱ/Ⅲ Clinical Study to Evaluate the Efficacy and Safety of GST-HG171/Ritonavir in Patients With Mild to Moderate COVID-19
100 Clinical Results associated with Atilotrelvir/Ritonavir
Login to view more data
100 Translational Medicine associated with Atilotrelvir/Ritonavir
Login to view more data
100 Patents (Medical) associated with Atilotrelvir/Ritonavir
Login to view more data
100 Deals associated with Atilotrelvir/Ritonavir
Login to view more data

R&D Status

10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
COVID-19
China
Fujian Akeylink Biotechnology Co., Ltd
23 Nov 2023
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
NCT05656443 (Corporate Publications)
ManualManual
Phase 2/3
COVID-19
1,227
(wzbgttrnfh) = xtqqojtrfy dkkkdpgpzw (jgpgmmxtuu )
Positive
23 Nov 2023
Placebo
(wzbgttrnfh) = xbsqzpbhaa dkkkdpgpzw (jgpgmmxtuu )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free